Testing divarasib after lung cancer surgery and chemotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had lung cancer (NSCLC) at stage II or III that was completely removed by surgery
- Your cancer has the KRAS G12C genetic mutation
- You received chemotherapy combined with immunotherapy (pembrolizumab or nivolumab) before surgery
- You are within 12 weeks after your surgery and have no signs of cancer returning
- You are in good enough health to tolerate treatment (ECOG score 0–1)
- You did not have severe side effects from your prior immunotherapy that haven't resolved
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
This program provides access to an investigational drug called divarasib for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It is for those whose cancer has grown after prior treatments, and it aims to see if the drug can help control the disease.
This trial tests a combination of two drugs (pembrolizumab and calderasib) after surgery for people with a specific type of lung cancer gene mutation called KRAS G12C. It aims to see if this therapy can help prevent the cancer from coming back.
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.